U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date

Visit link:
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease